Results 161 to 168 of about 6,029 (168)

Evaluation of the Relative Abuse of an OROS Extended-release Hydromorphone HCI Product

The Clinical Journal of Pain, 2018
Objective: Formulating prescription opioids to limit abuse remains a priority. OROS extended-release (ER) hydromorphone HCl (EXALGO) may have lower abuse potential than many other opioid products. Three postmarketing studies of the relative abuse liability of OROS hydromorphone ER were conducted.
Butler, Stephen F., McNaughton, Emily C., Black, Ryan A., Cassidy, Theresa A   +3 more
openaire   +3 more sources

Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectivesThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products.

Canadian Journal of Physiology and Pharmacology, 2007
Postmarket surveillance, particularly adverse reactions (ARs), forms an integral part of the ongoing safety evaluation for natural health products (NHPs). ARs can be related to many factors, including inherent toxicity, misuse, hypersensitivity, NHP–drug interactions, or product quality.
openaire   +1 more source

Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives.

Canadian journal of physiology and pharmacology, 2008
Postmarket surveillance, particularly adverse reactions (ARs), forms an integral part of the ongoing safety evaluation for natural health products (NHPs). ARs can be related to many factors, including inherent toxicity, misuse, hypersensitivity, NHP-drug interactions, or product quality. High consumer use and limited safety and efficacy data from human
openaire   +1 more source

Postmarket surveillance and returned product analysis: Success but not transparency

Heart Rhythm, 2013
Jonathan P, Piccini, Robert M, Califf
openaire   +2 more sources

Foundational development of a postmarket surveillance program for e-vapor products using Internet forum data

Drug and Alcohol Dependence, 2017
E.C. McNaughton, Taryn M. Dailey, M. Behling, Stephen F. Butler   +3 more
openaire   +1 more source

PostMarket Surveillance of Medical Products in the United States

2010
Paul J. Seligman, Thomas P. Gross, M. Miles Braun, Janet B. Arrowsmith   +3 more
openaire   +1 more source

[Publications and postmarketing product surveillance: why and how?].

Annales francaises d'anesthesie et de reanimation, 1998
openaire   +1 more source

Postmarketing surveillance study of a non-chlorofluorocarbon inhaler. Such studies initiated by manufacturer are designed to promote product.

BMJ (Clinical research ed.), 1999
openaire   +1 more source